Celgene Sues Barr Again Over Cancer Drug

Law360, New York (July 9, 2008, 12:00 AM EDT) -- Celgene Copr. has filed a second lawsuit accusing Barr Laboratories of infringing its patents for top-selling cancer drug Thalomid.

The suit, filed last week in the U.S. District Court for the Southern District of New Jersey, seeks both temporary and permanent injunctions as well as damages and attorneys' fees for infringing two patents.

Barr Laboratories has its own suit pending against Celgene, claiming that the company's patents are invalid and that it has violated the Sherman Act by attempting to block the sale of the cancer...
To view the full article, register now.




Law Firms



UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.